Company news

AC Immune SA news in 2021

AC Immune SA's news releases, calls and decks from 2021, newest first.

View company

AC Immune Awarded Two Michael J. Fox Foundation Grants to Advance Small Molecule Parkinson’s Disease Programs

December 14, 2021

AC Immune Announces Interim Phase 1b/2a Data Showing that its ACI-35.030 Anti-pTau Alzheimer’s Vaccine Generates a Potent Immune Response

November 11, 2021

AC Immune Reports Third Quarter 2021 Financial Results and Provides Corporate Update

November 7, 2021

AC Immune Extends Research Collaboration with University of Pennsylvania Focusing on the Pathogenic Protein TDP-43, a Major Driver of Neurodegenerative Diseases

November 3, 2021

AC Immune Holds its Extraordinary General Meeting and Appoints Monica Shaw, M.D., and Prof. Monika Bütler, Dr. oec., to its Board of Directors

October 28, 2021

AC Immune to Participate in Upcoming Virtual Investor Conferences in September

September 1, 2021

AC Immune Announces First Positive Cognitive Results for a Tau-Targeting Monoclonal Antibody in Alzheimer’s Disease

August 30, 2021

AC Immune Reports Second Quarter 2021 Financial Results and Provides Corporate Update

August 3, 2021

AC Immune Presents Full Phase 1b Results on Anti-Abeta Vaccine and Discusses its First-in-Class Diagnostic for Parkinson’s Disease at AAIC 2021

July 28, 2021

AC Immune Announces Strategic Acquisition of Industry-leading Parkinson’s Disease Vaccine Candidate and Equity Investment Led by Athos Service GmbH

July 26, 2021

AC Immune acquires AFFiRiS’ Specific Active Immunotherapy (SAIT) anti-alpha-synuclein programs targeting neurodegenerative diseases

July 26, 2021

AC Immune Holds its Annual General Meeting of Shareholders

June 24, 2021

AC Immune Provides Update on Alzheimer’s Disease Vaccine Candidates Targeting Pathological Amyloid-Beta

June 1, 2021

AC Immune Announces Expansion of Phase 1b/2a phospho-Tau Alzheimer’s Vaccine Trial and Provides a Program Update

May 16, 2021

AC Immune Reports First Quarter 2021 Financial Results and Provides Corporate Update

April 27, 2021

AC Immune Appoints Experienced Biotech and Investment Executive Dr. Alan Colowick to Board of Directors

March 30, 2021

AC Immune Reports Full-Year 2020 Financial Results and Provides 2021 R&D Outlook

March 22, 2021

AC Immune Announces New Clinical Results in Down Syndrome and Plans for Future Development of Anti-Amyloid-Beta Vaccine

March 15, 2021

AC Immune Presents New Preclinical Data for Therapeutic and Diagnostic Candidates Addressing Novel Targets for Neurodegenerative Diseases

March 8, 2021

AC Immune’s Alzheimer’s Vaccine Generates Potent Anti-pTau Antibody Response in a Phase 1b/2a Study

February 10, 2021

AC Immune Initiates Clinical Study of First-in-class Diagnostic for Parkinson’s Disease

February 7, 2021

AC Immune Reports Progress for Therapeutic Programs Targeting the NLRP3 Inflammasome Pathway

January 28, 2021

Decks in 2021